← FDA DRUG APPROVALS

FDA NDA · NDA019589

VANCENASE AQ

Sponsor: SCHERING

APPLICATION
NDA019589
TYPE
NDA
ORIGINAL APPROVAL
1987-12-23
LATEST ACTION
2000-08-30
ROUTE
NASAL
DOSAGE FORM
SPRAY, METERED
MARKETING STATUS
Discontinued

Products

VANCENASE AQDiscontinued
BECLOMETHASONE DIPROPIONATE MONOHYDRATE EQ 0.042MG DIPROP/SPRAY · SPRAY, METERED · NASAL

Approval history

2000-08-30Manufacturing (CMC) · Supplement 8 · standardAP
1995-06-15Manufacturing (CMC) · Supplement 4 · standardAP
1993-09-02Manufacturing (CMC) · Supplement 2 · standardAP
1993-09-02Manufacturing (CMC) · Supplement 3 · standardAP
1988-12-15Labeling · Supplement 1 · standardAP
1987-12-23Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →